Literature DB >> 8827016

Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.

U Stein1, W Walther, R H Shoemaker.   

Abstract

BACKGROUND: Multidrug resistance can be a major obstacle to successful cancer chemotherapy and is often associated with increased expression of the mdr1 (also known as P-glycoprotein) gene. Some of the proteins produced by the body's immune system, i.e., cytokines such as tumor necrosis factor-alpha (TNF) and interleukin 2 (IL-2), have been shown to modulate multidrug resistance. However, cytokines administered by the conventional intravenous method can cause severe side effects. Transduction of cytokine genes into tumor cells constitutes an alternative approach for production and release of the cytokine proteins in the local tumor microenvironment, which may reduce problems of toxicity associated with systemic administration.
PURPOSE: In this study, we investigated the therapeutic potential of a combination of gene therapy and chemotherapy on the basis of cytokine-mediated modulation of multidrug resistance in human colon carcinoma cells.
METHODS: Human colon carcinoma cell lines HCT15 and HCT116 were transduced with TNF or IL-2 carrying murine leukemia virus (MLV)-based retroviral vectors. Tumor cell clones were analyzed for cytokine expression by reverse transcriptase-polymerase chain reaction (RT-PCR) and by cytokine-specific enzyme-linked immunosorbent assays (TNF-ELISA or IL-2-ELISA). Expression of mdr1 messenger RNA (mRNA) was investigated using RT-PCR, and P-glycoprotein (Pgp) expression was determined by immunoflow cytometry with the monoclonal antibodies MRK16 and C219. The function of Pgp was analyzed by measuring accumulation of the fluorescent drug doxorubicin by flow cytometry. The XTT-(i.e., [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)]-5-[(phenylamino)-carbon yl-2H- tetrazolium hydroxide]-colorimetric cytotoxicity assay was used to determine chemosensitivity of cytokine gene-transfected tumor cells to doxorubicin and vincristine. Statistical significance was determined by the nonparametric Mann-Whitney rank sum test for the flow cytometry experiments (Pgp detection as well as drug uptake assays) and the parametric Student's t test for the chemosensitivity assay (XTT cytotoxicity assay). All P values reported were derived from two-sided statistical tests.
RESULTS: Transduction and expression of human TNF and IL-2 in HCT15 and HCT116 human colon carcinoma cell lines were found to reverse multidrug resistance. Both TNF and IL-2 secretion reduced mdr1 expression on the mRNA and Pgp levels (P < .0243). This result was associated with enhancement of doxorubicin accumulation within the cells (P < .0001). The cytokine-mediated effects on mdr1 expression resulted in increased chemosensitivity of the transduced cells to doxorubicin and vincristine (P < .0460). CONCLUSIONS AND IMPLICATIONS: We show that endogenous expression of cytokine genes in tumor cells and after transduction secretion of the related proteins, such as TNF and IL-2, can modulate multidrug resistance in vitro. This modulation enhances the susceptibility of the cells to the cytotoxic drugs. Our findings suggest the potential value of combined treatment of resistant tumors with gene therapy and chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827016     DOI: 10.1093/jnci/88.19.1383

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

1.  Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil.

Authors:  G Weinländer; G Kornek; M Raderer; M Hejna; C Tetzner; W Scheithauer
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 2.  Emerging role for drug transporters at the blood-testis barrier.

Authors:  Dolores D Mruk; Linlin Su; C Yan Cheng
Journal:  Trends Pharmacol Sci       Date:  2010-12-17       Impact factor: 14.819

3.  Synergistic effect of bromocriptine and tumor necrosis factor-alpha on reversing hepatocellular carcinoma multidrug resistance in nude mouse MDR1 model of liver neoplasm.

Authors:  Lei Ding; Xiao-Ping Chen; Zhi-Wei Zhang; Jian Guan; Wan-Guang Zhang; Hai-Ping Wang; Zhi-Hui Wang; Chun-Lei Li
Journal:  World J Gastroenterol       Date:  2005-09-28       Impact factor: 5.742

4.  Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models.

Authors:  R Minelli; S Occhipinti; C L Gigliotti; G Barrera; P Gasco; L Conti; A Chiocchetti; G P Zara; R Fantozzi; M Giovarelli; U Dianzani; C Dianzani
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

5.  Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter.

Authors:  Li-Peng Wu; Xi Wang; Lian Li; Ying Zhao; Shaoli Lu; Yu Yu; Wen Zhou; Xiangyu Liu; Jing Yang; Zhixin Zheng; Hui Zhang; Jingnan Feng; Yang Yang; Haiying Wang; Wei-Guo Zhu
Journal:  Mol Cell Biol       Date:  2008-03-10       Impact factor: 4.272

6.  Self-assembled polyethylenimine-graft-poly(epsilon-caprolactone) micelles as potential dual carriers of genes and anticancer drugs.

Authors:  Li Yan Qiu; You Han Bae
Journal:  Biomaterials       Date:  2007-06-20       Impact factor: 12.479

7.  Cytokine-mediated reversal of multidrug resistance.

Authors:  U Stein; W Walther
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

8.  Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cells.

Authors:  U Stein; C Fleuter; F Siegel; J Smith; A Kopacek; D A Scudiero; K M Hite; P M Schlag; R H Shoemaker; W Walther
Journal:  Br J Cancer       Date:  2012-03-29       Impact factor: 7.640

9.  Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder.

Authors:  M Milella; J Jacobelli; F Cavallo; A Guarini; F Velotti; L Frati; R Foà; G Forni; A Santoni
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.